078140.KQ Daebongls.Co.Ltd
- Market cap
- KRW 71.7B
- P/E
- -
- P/B
- 0.51x
- ROE
- 1.7%
- Dividend yield
- 1.42%
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 078140.KQ undervalued?
Graham numberThe Graham number of Daebongls.Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daebongls.Co.Ltd fundamental analysis
13 of 22 checks passedROE 0/2
Low return on equity (1.7%), below 10%.
ROA 0/1
Return on assets (0.8%) is below the industry median (4.7%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (37.0%) is above the 5-year average (11.7% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (37.0%) is above the industry median (-16.9%).
Revenue Growth 1/2
Revenue grew 3.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (47.8%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.3x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.5x) is below the industry median (0.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.4%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 10.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Daebongls.Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daebongls.Co.Ltd
Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally. The company's Cosmetic Ingredients division offers special cosmetic ingredients comprising fresh green tea, black ginseng water, jeju hatban extract, wormwood extract, jeju camellia oil, jeju dang oil extract, jeju basalt powder, jeju active complex, and ginseng flower extract; and natural and synthesis…
Full company profileDaebongls.Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daebongls.Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 71.0B | 65.7B | 71.8B | 69.5B | 76.3B | 83.0B | 93.5B | 87.6B | 94.0B | 102B | 125B |
| Gross Profit | 20.3B | 19.5B | 19.1B | 18.9B | 20.7B | 23.6B | 25.0B | 21.4B | 26.8B | 28.5B | 33.9B |
| Operating Income | 11.2B | 9.14B | 7.92B | 7.18B | 8.12B | 9.69B | 8.17B | 3.80B | 9.05B | 7.33B | 11.3B |
| EBITDA | - | - | - | - | - | - | 14.3B | 10.3B | 14.6B | 21.0B | 14.2B |
| Net Income | 8.39B | 7.14B | 6.22B | 5.73B | 5.82B | 6.79B | 8.63B | 4.18B | 7.34B | 10.1B | 2.35B |
| EPS | 757 | 644 | 561 | 517 | 529 | 620 | 788 | 382 | 670 | 919 | 214 |
| Balance Sheet | |||||||||||
| Total Assets | 75.4B | 80.4B | 86.9B | 102B | 150B | 163B | 186B | 195B | 239B | 265B | 277B |
| Total Liabilities | 12.5B | 11.2B | 12.3B | 21.3B | 46.0B | 53.8B | 69.0B | 41.7B | 107B | 90.0B | 101B |
| Shareholders' Equity | 62.9B | 69.2B | 74.6B | 80.8B | 104B | 109B | 117B | 121B | 132B | 141B | 142B |
| Cash & Short-term Investments | 15.5B | 16.7B | 21.5B | 30.6B | 70.9B | 62.9B | 90.2B | 76.4B | 75.8B | 7.62B | 10.5B |
| Total Debt | 846M | 509M | 325M | 6.22B | 5.99B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.53B | 8.41B | 8.77B | 6.05B | 15.7B | 10.1B | 8.78B | 5.89B | 14.3B | 8.91B | 7.10B |
| Capital Expenditure | 3.54B | 3.92B | 3.60B | 7.16B | 8.57B | 6.32B | 5.67B | 9.59B | 26.5B | 39.6B | 2.38B |
| Free Cash Flow | - | - | - | - | 7.03B | 3.68B | 3.10B | -3.70B | -12.1B | -30.7B | 4.72B |
| Ratios | |||||||||||
| ROE | 13.3% | 10.3% | 8.3% | 7.1% | 5.6% | 6.2% | 7.4% | 3.5% | 5.6% | 7.1% | 1.7% |
| ROA | 11.1% | 8.9% | 7.2% | 5.6% | 3.9% | 4.2% | 4.6% | 2.1% | 3.1% | 3.8% | 0.8% |
| Net Profit Margin | 11.8% | 10.9% | 8.7% | 8.2% | 7.6% | 8.2% | 9.2% | 4.8% | 7.8% | 9.9% | 1.9% |
| Debt to Equity | 0.01x | 0.01x | 0.00x | 0.08x | 0.06x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Daebongls.Co.Ltd dividends
- Dividend yield
- 1.42%
- Forward dividend
- -
- Payout ratio
- 10.2%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.02B | 93 | 10.2% |
| 2024 | KRW 926M | 85 | 12.6% |
| 2023 | KRW 1,000M | 91 | 23.9% |
| 2022 | KRW 1.03B | 94 | 11.9% |
| 2021 | KRW 551M | 50 | 8.1% |
| 2020 | KRW 554M | 50 | 9.5% |
| 2019 | KRW 554M | 50 | 9.7% |
| 2018 | KRW 554M | 50 | 8.9% |
| 2017 | KRW 554M | 50 | 7.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 30, 2011.
Who owns Daebongls.Co.Ltd
- Insiders 50.95%
- Institutions 0.50%
- Public & others 48.56%
- Shares outstanding 11.1M
- Free float 5.37M
Daebongls.Co.Ltd company profile
- Company name
- Daebongls.Co.Ltd
- Ticker
- 078140.KQ
- ISIN
- KR7078140001
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Chemicals
- Employees
- 123
- Fiscal year end
- December
- Address
- 123 Neungheodae-ro 649 beon-gil, Incheon, South Korea, 21697
- Phone
- 82 3 2712 8800
- Website
- daebongls.co.kr
About Daebongls.Co.Ltd
Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally. The company's Cosmetic Ingredients division offers special cosmetic ingredients comprising fresh green tea, black ginseng water, jeju hatban extract, wormwood extract, jeju camellia oil, jeju dang oil extract, jeju basalt powder, jeju active complex, and ginseng flower extract; and natural and synthesis cosmetics like moisturizing, skin protection, whitening, anti- aging, skin care, and hair care products. The company's Pharmaceutical Raw Material division develops the API of respiratory, hypertension, digestive-system treatments, and medicines and supply excipients to domestic companies as an agent for global companies. The company's Food & Feed division manufactures and distributes functional additives, protein products, amino acids, and vitamins. Daebongls.Co.,Ltd. was founded in 1986 and is headquartered in Incheon, South Korea.
Daebongls.Co.Ltd management
4- Mr. Jin-Oh ParkChief Exec. Officer · born 1971
- Mr. Jong-Ho ParkFounder
- Mr. Chang-Woo SonDirector of Fin. Management Department and Director · born 1967
- Mr. Yong-Kil KimChief of R&D and Director · born 1960